Predictors of Antiviral Therapy in a Post-Transfusion Cohort of Hepatitis C Patients
INTRODUCTION: In the past, antiviral therapy has been given to 15% to 30% of patients infected with hepatitis C virus (HCV). The efficacy of therapy has recently improved with the addition of ribavirin and pegylated interferon. The aim of the present study was to identify the clinical, socioeconomic...
Saved in:
Main Authors: | Maciej Witkos, Qi-Long Yi, Jenny Heathcote, Moira K Kapral, Murray D Krahn |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2006-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2006/638272 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disease Burden of Chronic Hepatitis B among Immigrants in Canada
by: William WL Wong, et al.
Published: (2013-01-01) -
Health Care Costs Associated with Hepatitis C: A Longitudinal Cohort Study
by: Mel Krajden, et al.
Published: (2010-01-01) -
Recent Advances in Antiviral Therapy for Chronic Hepatitis C
by: Akihiro Tamori, et al.
Published: (2016-01-01) -
Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C
by: Louis WC Liu, et al.
Published: (2003-01-01) -
Transfusion-transmitted hepatitis E
by: LI Baixun, et al.
Published: (2025-01-01)